Sigrid Therapeutics develops clinically validated, non-systemic solutions for blood-sugar control and weight management based on its silica-particle SiPore® platform, which operates mechanically in the gut without entering systemic circulation. Its leading product, Glucose Stabiliser, is sold direct-to-consumer and through a growing U.S. physician network, achieving more than 3× revenue growth over the past year, evidencing strong product-market fit and repeat usage. The company is pursuing CE-mark authorization for an over-the-counter medical device targeting adults with excess weight and elevated blood sugar, and is also extending SiPore® into oral care, veterinary health, and food technology via prospective licensing partnerships. Founded on more than 15 years of research, Sigrid positions itself as a scalable platform business that can power multiple consumer-health categories. The fresh capital will accelerate U.S. expansion and regulatory efforts while supporting new vertical development. To date, Sigrid has raised approximately USD 27 million in total funding.

Total raised

$19M

Funding rounds

4

Latest round

Equity

Latest activity

Jan 2026